BioSpace News Archive

Foldax® announced today that it has been selected as Company of the Year among 10 cardiovascular device company finalists by MedTech Outlook Magazine. Foldax was honored for its innovative Tria™ heart valve, the first biopolymer heart valve to receive FDA approval for a U.S. clinical trial. Foldax has reinvented every aspect of the artificial heart valve – from material to design to manufacturing – to develop sur

Trait products largely relate to fungal-disease resistance and herbicide resistance in canola, further bolstering Cibus’ position as a leader in non-GMO input and agronomy traits SAN DIEGO--( BUSINESS WIRE )-- Cibus, a leader in input and agronomy trait products, announced today an additional 12 of its trait products have been designated as non-regulated by the United States Department of Agriculture’s Animal and Plant Health Inspection Service (USDA

ReCode Therapeutics™ (ReCode) (the Company), a private biopharmaceutical company pioneering disease-modifying medicines for the treatment of life-limiting respiratory diseases, today announced the appointment of Julie Eastland as chief operating officer (COO) and chief financial officer (CFO

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will host a Twist Biopharma Analyst & Investor Event on Friday, October 23, 2020. The event is scheduled to take place from 11:00 a.m. – 1:00 p.m. ET in a virtual format. The event will include an overview of Twist

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2020 financial results on Thursday, November 5, 2020. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, November 5, 2020 to discuss its third quarter 2020 financial results. The call may be accessed

Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced that it will participate virtually in two upcoming conferences in October: TCR-based Therapies Summit Title: ARTEMIS ® Antibody TCR T Cell Therapies for Solid Tumors Speaker: Cheng Liu, Ph.D., President and CEO Date: Tuesday, October 27, 2020 Time: 9:00 a.m

Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Michael D. Harvey, PhD as Senior Vice President, Drug Development. In his position, Dr. Michael Harvey will be responsible for overseeing all R&D activities pertaining to CMC, nonclinical development, and regulatory affairs. “As we grow our operations, I am pleased to welcome Michael to our leader

Alkame Holdings, Inc., a publicly traded holding company announced that in an effort to strengthen operations and innovation has named Craig Kaufman as Chairman of the company’s Board of Directors as well as hired several key additions to the executive leadership team.

Avient Biosciences officially launched its 200,000-square-foot industrial hemp research and extraction facility in North Carolina’s Research Triangle region this week. Designed for full cGMP compliance (21 CFR Parts 210 and 211),

Sharps Compliance Corp. announced that it will release its first quarter 2021 results for the period ended September 30, 2020, before the opening of the financial markets on Tuesday, October 27, 2020.